Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCh63 AMA1 + AMA1-C1 + Alhydrogel + CPG 7909
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Modified DNA Aptamers → DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
This is a multi-component experimental malaria vaccine regimen targeting *Plasmodium falciparum*. It combines a viral vector (chimpanzee adenovirus serotype 63, AdCh63) encoding the apical membrane antigen 1 (AMA1), a recombinant protein vaccine containing two allelic forms of AMA1 (AMA1-C1), the adjuvant Alhydrogel (aluminum hydroxide), and the immunostimulatory CpG oligodeoxynucleotide adjuvant CPG 7909. The combination aims to induce both strong humoral and cellular immune responses against blood-stage malaria parasites. The viral vector primes T cell responses, while the protein/adjuvant components boost antibody production. This approach is under clinical investigation for malaria prevention[3][6][10].
- Other names
- Apical Membrane Antigen 1 Combination Vaccine with Alhydrogel and CPG 7909
02
Targets
TLR9 (Toll-like receptor 9)AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on AdCh63 AMA1 + AMA1-C1 + Alhydrogel + CPG 7909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCh63 AMA1 + AMA1-C1 + Alhydrogel + CPG 7909.